Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 13:11:5473-5480.
doi: 10.2147/CMAR.S203059. eCollection 2019.

Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors

Ding-Ding Yan  1 , Qiu Tang  1 , Jian-Hong Chen  1 , Ye-Qiang Tu  1 , Xiao-Juan Lv  1
Affiliations

Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors

Ding-Ding Yan et al. Cancer Manag Res. .

Abstract

Objective: To determine the predictive value of the 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer patients with surgical risk factors. Methods: Data of 662 cervical cancer patients (stages IB and IIA) with surgical risk factors treated at Zhejiang Cancer Hospital between 2008 and 2011 were retrospectively reviewed. Univariate log-rank test and multivariate Cox regression models were adopted to evaluate the relationship between 2018 FIGO stage and survival. Results: On re-staging of patients, 17.3%, 44.5%, 25.4%, and 37.1% of the patients with FIGO 2009 stage IB1, IB2, IIA1, and IIA2, respectively, were upgraded to FIGO 2018 IIIC1P stage, and 2.1%, 3.0%, 3.1%, and 2.1% patients, respectively, were upgraded to IIIC2P stage. The 5-year overall survival (OS) rates of patients with FIGO 2018 stage IB1, IB2, IB3, IIA1, IIA2, IIIC1P, and IIIC2P were 95.3%, 95.1%, 90.4%, 92.4%, 86.4%, 81.9%, and 56.3%, respectively. The 5-year progression-free survival (PFS) rates were 94.0%, 91.0%, 88.5%, 91.4%, 86.4%, 79.5%, and 43.8%, respectively. The 5-year OS rates of patients with 1-2 positive pelvic lymph nodes (PLNs) and those with >2 positive PLNs were 86.0% and 73.7%, respectively, and the 5-year PFS rates were 84.2% and 70.2%, respectively. OS and PFS of patients with 1-2 positive PLNs in stage IIIC1P were similar to those of patients in stage IIA2 without lymph node metastasis, but significantly better than those of patients with >2 positive PLNs. Multivariate analysis showed FIGO 2018 stage to be an independent prognostic factor for OS and PFS. Conclusion: The 2018 FIGO staging system for cervical cancer appears to be useful for predicting prognosis of patients with risk factors after radical surgery. Survival of stage IIA1 patients is better than that of stage IB3 patients. Stage IIIC1 is not homogenous; survival in stage IIIC1P depends on the number of positive PLNs.

Keywords: 5-year overall survival; 5-year progression-free survival; FIGO staging system; cervical cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
(A and B) PFS and OS curves for 2018 FIGO stages. (C and D) PFS and OS curves for patients with different numbers of metastatic PLNs. Abbreviations: OS, overall survival; PFS, progress-free survival; RT, radiotherapy; FIGO, International Federation of Gynecology and Obstetrics; PLN, pelvic lymph node.
See this image and copyright information in PMC

References

    1. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73(2):177–183. doi: 10.1006/gyno.1999.5387 - DOI - PubMed
    1. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB. Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol. 2005;99(1):106–112. doi: 10.1016/j.ygyno.2005.05.026 - DOI - PubMed
    1. Ryu SY, Park SI, Nam BH, et al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors? Int J Radiat Oncol Biol Phys. 2011;79(3):794–799. doi: 10.1016/j.ijrobp.2009.11.019 - DOI - PubMed
    1. Samlal RA, van der Velden J, Schilthuis MS, et al. Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma. Gynecol Oncol. 1997;64(3):463–467. - PubMed
    1. Inoue T, Okumura M. Prognostic significance of parametrial extension in patients with cervical carcinoma Stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation. Cancer. 1984;54(8):1714–1719. - PubMed